Company intelligence / Profile preview

iCardiac Technologies

Rochester, New York, United States

Ownership: Private
Employees: ~75
Development stage: Other

Overview

iCardiac Technologies provided advanced ECG-based cardiac safety services, including high-precision QT and early precision QT methodologies for clinical trials. It served as a centralized core laboratory for the majority of the top global pharmaceutical companies prior to its acquisition by ERT in 2017.

Therapeutic areas: Cardiovascular
Modalities: DeviceNon-pharmacological therapy
Industry: Contract Research Organization

Partnerships

Pfizer (multiyear research alliance for advanced ECG)Numerous top 10 pharmaceutical and biotech companies

Beyond the preview

Go deeper on iCardiac Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iCardiac Technologies.

Explore the full profile